Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.

Detalles Bibliográficos
Autores principales: Ghanekar, Shaila D, Miller, Wai Wai, Meyer, Colin J, Fenelon, Kevin J, Lacdao, Alvin, Zesiewicz, Theresa A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800542/
https://www.ncbi.nlm.nih.gov/pubmed/31686946
http://dx.doi.org/10.2147/DNND.S180027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800542/
https://www.ncbi.nlm.nih.gov/pubmed/31686946
http://dx.doi.org/10.2147/DNND.S180027

Ejemplares similares